Viela Bio’s Uplizna Therapy Gets FDA Approval

The FDA approved Uplizna injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder in adult patients with a particular antibody.

• NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord. Uplizna is only the second approved treatment for the disorder
• The FDA granted approval of Uplizna to Viela Bio

To view the source of this information click here

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2020 Bloomberg ...